Evidence map›Paper›PMID 40868003›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Borderline Oxacillin-Resistant

Beverly Buffart, Philippe Clevenbergh, Alina Stiuliuc, Ioannis Raftakis, Mony Hing, Véronique Yvette Miendje Deyi, Olivier Denis, Delphine Martiny, Nicolas Yin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Beverly BuffartDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.ORCID 0000-0001-5879-3072
Philippe ClevenberghInfectious Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles (ULB), 1090 Brussels, Belgium.
Alina StiuliucRhumatologic Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles (ULB), 1090 Brussels, Belgium.
Ioannis RaftakisRhumatologic Diseases Department, University Hospital Brugmann, Université Libre de Bruxelles (ULB), 1090 Brussels, Belgium.
Mony HingDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.
Véronique Yvette Miendje DeyiDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.
Olivier DenisDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.
Delphine MartinyDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.ORCID 0000-0001-9307-7418
Nicolas YinDepartment of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.ORCID 0000-0003-1706-6869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBorderline oxacillin-resistant CASE PRESENTATION: A 39-year-old woman with systemic lupus erythematosus was admitted for a suspected exacerbation, complicated by multiple serositis and nephritis. She was on chronic treatment with methylprednisolone and hydroxychloroquine. On admission, she was afebrile. Laboratory investigations revealed elevated C-reactive protein and increased D-dimer levels. Later, she developed a septic peripheral venous thrombophlebitis, and treatment was adjusted to amoxicillin-clavulanate. Blood cultures grew

conclusionsThis case highlights the complexity of managing a patient with an uncommon and poorly documented infection. The lack of data on BORSA infections and the difficulties in detecting and treating them led to a prolonged delay in the appropriate management of this patient.

Indexed as

bacteremiaBORSAmethicillin resistanceStaphylococcus aureus

Identifiers

PMID40868003
PMCPMC12382784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.